XML 30 R20.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has one operating segment. The Company's operating segment discovers and develops therapies for CNS disorders. The Company's chief operating decision maker ("CODM"), its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of assessing performance and allocating resources based on net loss that also is reported on the condensed consolidated statement of operations as consolidated net loss. Net loss is used by the CODM to make key strategic and operational decisions. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. The majority of the Company's long-lived assets are held in the United States.
The following table presents selected financial information about the Company's single operating segment for the three months ended March 31, 2026 and 2025 (in thousands):
Three Months Ended
March 31,
20262025
Program-specific expenses:
Ulixacaltamide$19,103 $23,513 
Vormatrigine20,494 13,733 
Relutrigine12,854 5,377 
Elsunersen3,197 761 
Other early stage assets3,242 1,105 
Personnel-related expenses17,730 13,030 
Stock-based compensation expense17,112 8,786 
Depreciation expense39 47 
Other segment expenses(a)
12,089 8,376 
Other income, net13,299 5,432 
Consolidated net loss$(92,561)$(69,296)
(a) Other segment expenses includes research and development and general and administrative costs not attributable to a specific program.